NTRK and PDL1 (SP142)

IHC in INP

N-TRK ^{VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.}

 

The IHC screening test consists of a multiplex pan-RTK antibody cocktail, which uses a single tissue section to simultaneously assess for TrkA, TrkB and TrkC (encoded by NTRK1, NTRK2 and NTRK3 respectively).

NTRK genes are oncogenes that can undergo genetic rearrangement, resulting in altered TRK proteins.

 

These altered proteins can activate signaling pathways involved in proliferation of certain types of cancer including lung, thyroid, sarcoma, infantile fibrosarcoma, secretory and juvenile breast cancer and mammary analogue secretory cancers of the salivary glands, NTRK fusion proteins are likely to be the defining genetic feature.

It has been shown that patients with tumors driven by these gene rearrangements are excellent candidates for targeted RTK inhibitor therapies.

PDL1 ^{Ventana PD-L1 SP142 Assay is the only FDA approved test for TECENTRIQ}

FDA Approval (March 13, 2019):

-VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti PD-L1 clone SP142 intended for use in the assessment of the programmed death-ligand 1 (PD-L1) protein.

-Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.

- VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies for the following tumors:

   Urothelial Carcinoma patients (UC)

   Triple-Negative Breast Carcinoma patients (TNBC)

   Non-small cell lung cancer patients (NSCLC)

PDL1(SP142) assay gives you the confidence to guide immunotherapy decisions in UC, TNBC and NSCLC.

Other tests available

As usual our purpose is the satisfaction of our patients by delivering new tests combined with high quality.

Now these tests are available in INP:

EGFR, ALK, ROS1, KRAS, NRAS, BRAF, PDL1 (22C3 and SP142), NTRK